PatriciaSBralyMD

PubMed

• 27 citations
  Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study
  Molly Brewer, Roberto Angioli, Giovanni Scambia, Domenica Lorusso, Corrado Terranova, Pierluigi Benedetti Panici, Francesco Raspagliesi, Paolo Scollo, Francessco Plott...> ;Gynecologic Oncology. 2020 Mar 1
• 42 citations
  A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
  Amit M. Oza, Ursula A. Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D. Roman, Sarah P. Blagden, Susana Banerjee, William P. McGuire, Sharad A. Ghamande, M...> ;Clinical Cancer Research. 2020 Mar 1
• 22 citations
  A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma
  Richard T. Penson, Kathleen M. Moore, Gini F. Fleming, Patricia S. Braly, Veronica L. Schimp, Hoa Nguyen, Ursula A. Matulonis, Susana Banerjee, Paul Haluska, Martin Go...> ;Gynecologic Oncology. 2014 Sep 1
• 16 citations
  A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
  Thomas J. Herzog, Bradley J. Monk, Peter G. Rose, Patricia S. Braly, Jeffrey F. Hines, Maria C. Bell, Robert M. Wenham, Angeles Alvarez Secord, Lynda D. Roman, Mark H....> ;Gynecologic Oncology. 2014 Mar 1
• 82 citations
  Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
  Nicoletta Colombo, D. S. McMeekin, Peter E. Schwartz, Cristiana Sessa, R. Holloway, Patricia S. Braly, Daniela Matei, Anne Morosky, P. F. Dodion, M. H. Einstein, Frank...> ;British Journal of Cancer. 2013 Mar 19
• 15 citations
  Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.
  D.S. McMeekin, A. Lisyanskaya, Marta A. Crispens, Amit M. Oza, Patricia S. Braly, D. Doering, E. Bayever, B. Michiels, Maurie Markman> ;Gynecologic Oncology. 2009 Aug 1
• Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
  Rose PG, Drake R, Braly PS, Bell MC, Wenham RM, Hines JH, Alvarez-Secord A, Soltes-Rak E, Childs BH, Herzog TJ> ;J. Clin. Oncol.. 2009-05-20
• 47 citations
  The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy i...
  Patricia S. Braly, Christopher F. Nicodemus, Christina Chu, Yvonne Collins, Robert Edwards, Alan N. Gordon, William McGuire, Christopher Schoonmaker, Theresa L. Whites...> ;Journal of Immunotherapy. 2009 Jan 1
• Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovari...
  Finkler NJ, Dizon DS, Braly P, Micha J, Lassen U, Celano P, Glasspool R, Crowley E, Buhl-Jensen P, Penson RT> ;J. Clin. Oncol.. 2008-05-20
• 77 citations
  A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
  Carolyn N. Krasner, D. S. McMeekin, Steve Chan, Patricia S. Braly, F G Renshaw, Stan B. Kaye, D. Provencher, Susana M. Campos, Martin Gore> ;British Journal of Cancer. 2007 Dec 11
• 1 citations
  A pilot study to evaluate the safety and clinical outcomes of once-weekly epoetin alfa 80,000 u in anemic patients with cancer receiving chemotherapy.
  Roger J. Waltzman, Denise Williams, Patricia Braly> ;Supportive Cancer Therapy. 2005 Oct 1
• Final results of a phase II study of weekly trabectedin in second/third line ovarian carcinoma.
  McMeekin DS, Krasner C, Chan S, Braly P, Kaye S, Provencher D, Trifan OC, Michiels B, Gore M> ;J. Clin. Oncol.. 2005-06-01
• 57 citations
  Prevalence of human papillomavirus genotypes in women from three clinical settings.
  Anil K. Chaturvedi, Jeanne Dumestre, Ann M. Gaffga, Kristina M. Mire, Rebecca A. Clark, Patricia S. Braly, Kathleen Dunlap, Tracy E. Beckel, Ansley F. Hammons, Patrici...> ;Journal of Medical Virology. 2005 Jan 1
• Treatment of anemia with epoetin alfa 80,000 U QW in cancer patients receiving chemotherapy.
  Tarabay G, Braly P, Baker JJ, Williams D, Waltzman RJ> ;J. Clin. Oncol.. 2004-07-15
• A phase II study of weekly trabectedin (ET-743) in second/third line ovarian carcinoma.
  Krasner CN, McMeekin S, Chan S, Braly P, Kaye S, Provencher D, Klecz J, Michiels B, Van de Velde H, Gore M> ;J. Clin. Oncol.. 2004-07-15
• A phase II study of trabectedin (ET-743) as a second line therapy in patients with persistent or recurrent endometrial carcinoma.
  McMeekin DS, Manikas G, Crispens M, Orza AM, Braly P, Doering D, Trifan OC, Michiels B, Markman M> ;J. Clin. Oncol.. 2004-07-15
• 16 citations
  Distribution of human papillomavirus type 16 variants in human immunodeficiency virus type 1-positive and -negative women.
  Anil K. Chaturvedi, Joeli A. Brinkman, Ann M. Gaffga, Jeanne Dumestre, Rebecca A. Clark, Patricia S. Braly, Kathleen Dunlap, Patricia Kissinger, Michael E. Hagensee> ;The Journal of General Virology. 2004 May 1
• 134 citations
  ZYC101a for Treatment of High-Grade Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial
  Francisco A.R. Garcia, Karl Ulrich Petry, Laila I. Muderspach, Michael A. Gold, Patricia S. Braly, Christopher P. Crum, Marianne Magill, Michael H. Silverman, Robert G...> ;Obstetrics and Gynecology. 2004 Feb 1
• 40 citations
  Combined Intraperitoneal and Intravenous Chemotherapy for Women With Optimally Debulked Ovarian Cancer: Results From an Intergroup Phase II Trial
  Mace L. Rothenberg, P.Y. Liu, Patricia S. Braly, Sharon P. Wilczynski, Edward V. Hannigan, Scott Wadler, Gavin Stuart, Caroline Jiang, Maurie Markman, David S. Alberts> ;Journal of Clinical Oncology. 2003 Apr 1
• 5 citations
  Reporting the potential benefits of new technologies for cervical cancer screening.
  Patricia Braly, Thomas V. Sedlacek, Walter Kinney, Ellen E. Sheets, Leslie A. Walton, Frederick Farber, J. Thomas Cox> ;Journal of Lower Genital Tract Disease. 2001 Apr 1
• 15 citations
  Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
  Robert J. Morgan, Patricia Braly, Lucille Leong, Stephen Shibata, Kim Margolin, George Somlo, Mark McNamara, Jeff Longmate, Stanley Schinke, James Raschko, Stuart Naga...> ;Gynecologic Oncology. 2000 Jun 1
• 437 citations
  Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Onc...
  Franco M. Muggia, Patricia S. Braly, Mark F. Brady, Gregory P. Sutton, Theodore H. Niemann, Samuel L. Lentz, Ronald D. Alvarez, Paul R. Kucera, James M. Small> ;Journal of Clinical Oncology. 2000 Jan 1
• 6 citations
  Phase II Trial of Intraperitoneal Cisplatin with Intravenous Doxorubicin and Cyclophosphamide in Previously Untreated Patients with Advanced Ovarian Cancer—Long-Term F...
  Robert J. Morgan, Patricia Braly, Gary Cecchi, Lucille Leong, Stephen Shibata, Kim Margolin, George Somlo, Mark McNamara, Jeff Longmate, Stanley Schinke, James Raschko...> ;Gynecologic Oncology. 1999 Dec 1
• 2 citations
  DNA Content and S-Phase Fraction in Epithelial Ovarian Cancer: What Information Do They Really Add?
  Patricia S. Braly> ;Gynecologic Oncology. 1998 Oct 1
• 23 citations
  Phase I and pharmacokinetic study of intraperitoneal topotecan.
  Steven C. Plaxe, R D Christen, John O'Quigley, Patricia S. Braly, James L. Freddo, Edward F. McClay, Dennis D. Heath, Stephen B. Howell> ;Investigational New Drugs. 1998 Jan 1
• Join now to see all